These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32979560)

  • 1. Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy.
    Krystal AD; Mittoux A; Lindsten A; Baker RA
    J Affect Disord; 2021 Jan; 278():288-295. PubMed ID: 32979560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
    Krystal AD; Mittoux A; Meisels P; Baker RA
    Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
    Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
    Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial.
    Carpenter JS; Zmicerevska N; Crouse JJ; Nichles A; Garland A; Song YJC; Wilson C; Rohleder C; McHugh C; Leweke FM; Koethe D; Scott EM; Hickie IB
    BMJ Open; 2022 Sep; 12(9):e056298. PubMed ID: 36691133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
    Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
    J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
    Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
    Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
    Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
    Lepola U; Hefting N; Zhang D; Hobart M
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
    McIntyre RS; Weiller E; Zhang P; Weiss C
    J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
    Newcomer JW; Eriksson H; Zhang P; Meehan SR; Weiss C
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31577867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies.
    McIntyre RS; Bubolic S; Zhang Z; MacKenzie EM; Therrien F; Miguelez M; Boucher M
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):133-140. PubMed ID: 38421922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
    Hobart M; Zhang P; Weiss C; Meehan SR; Eriksson H
    Int J Neuropsychopharmacol; 2019 Mar; 22(3):173-179. PubMed ID: 30508090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.
    Katzman MA; Therrien F; MacKenzie EM; Wang F; de Jong-Laird A; Boucher M
    J Affect Disord; 2022 Nov; 316():201-208. PubMed ID: 35970327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.